Testosterone Therapy and Elevated Blood Count Overview

Testosterone therapy can increase red blood cell production, measured by hemoglobin (Hb) and hematocrit (Hct) levels. Hemoglobin is the oxygen-carrying protein in red blood cells, while hematocrit represents the percentage of blood composed of red blood cells. This increase occurs because testosterone stimulates erythropoietin, a hormone that promotes red blood cell production.

Safe Levels and Monitoring

Elevated red blood cell counts can thicken blood, potentially causing symptoms like headaches or dizziness. Monitoring is crucial for both men and women on testosterone therapy. Safe thresholds include:

- **Hemoglobin**: Below 18 g/dL (180 g/L).
- **Hematocrit**: Below 54% for all patients; for women, action may be taken at 48–50% depending on symptoms or comorbidities. If levels exceed these limits, adjustments are needed to prevent complications.

Managing High Levels

If hemoglobin or hematocrit exceeds safe limits:

- Reduce testosterone dosage.
- Consider phlebotomy (blood donation) to lower red blood cell counts.
- Continue regular monitoring to maintain safe levels.

Key Points

- Testosterone therapy increases red blood cell production, tracked via hemoglobin and hematocrit tests.
- Safe limits: Hemoglobin <18 g/dL, hematocrit <54% (with earlier intervention at 48–50% for women if symptomatic or increased risk -other medical conditions, e.g., polycythemia).
- **No strong evidence links moderately elevated red blood cell counts from testosterone to blood clots unless other medical conditions are present.**
- Adjustments (lowering dose, pausing therapy, or phlebotomy) are recommended if levels are too high.
- Staying hydrated before blood tests ensures accurate results, as dehydration can falsely elevate hemoglobin and hematocrit by 10–15% (e.g., Hb up by 1–2 g/dL, Hct up by 4–7%).

Hematocrit and Hemoglobin Guidelines for Women

- **Hematocrit**: Normal target ≤48%; intervention required at ≥54% (dose reduction, therapy pause, or phlebotomy).
- **Hemoglobin**: Safe upper limit is 18 g/dL; typical baseline for women is 12–15 g/dL, so symptoms at lower values may warrant attention.

Dehydration and Blood Test Accuracy

Dehydration can falsely elevate hemoglobin, hematocrit, and lipid levels:

- **Hemoglobin**: Increases by 1–2 g/dL (10–15%).
- **Hematocrit**: Increases by 4–7% (10–15%).
- **Lipids**: Total cholesterol, LDL, and HDL may appear 8–12% higher; triglycerides are less affected but may still rise slightly. Drinking water before blood tests (for blood count or lipids) is essential for accurate results, as dehydration concentrates blood components, leading to misleadingly high readings.

Summary

Testosterone therapy can elevate red blood cell counts, requiring regular monitoring of hemoglobin and hematocrit. If levels become too high, lowering the dose or donating blood can help. Staying hydrated before blood tests ensures accurate hemoglobin, hematocrit, and lipid results, preventing false positives for elevated levels.

References

.

1. Bhasin, S., Brito, J. P., Cunningham, G. R., et al. (2020). Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. *The Journal of Clinical Endocrinology & Metabolism*, 105(5), 1–30. https://doi.org/10.1210/clinem/dgaa054
2. Lozano, R., Naghavi, M., Foreman, K., et al. (2020). Testosterone replacement therapy and cardiovascular risk: A systematic review and meta-analysis. *The Lancet Healthy Longevity*, 1(2), e74–e85. https://doi.org/10.1016/S2666-7568(20)30011-4
3. Martinez, C., Suissa, S., Rietbrock, S., et al. (2018). Testosterone treatment and risk of venous thromboembolism: Population-based case-control study. *Thrombosis Research*, 171, 36–42. https://doi.org/10.1016/j.thromres.2018.09.042
4. Ohlander, S. J., Varghese, B., Pastuszak, A. W., et al. (2014). Erythrocytosis following testosterone therapy. *Sexual Medicine Reviews*, 6(1), 77–85. https://doi.org/10.1016/j.sxmr.2017.04.001
5. Sharma, R., Oni, O. A., Gupta, K., et al. (2015). Normalization of testosterone levels after testosterone replacement therapy is not associated with increased risk of myocardial infarction or stroke: The role of erythrocytosis. *Mayo Clinic Proceedings*, 90(9), 1200–1210. https://doi.org/10.1016/j.mayocp.2015.06.015
6. Snyder, P. J., Bhasin, S., Cunningham, G. R., et al. (2018). Effects of testosterone treatment in older men. *New England Journal of Medicine*, 374(7), 611–624. https://doi.org/10.1056/NEJMoa1506119